Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled salbutamol for transient tachypnea of the newborn
IRCT20250722066594N1Phase 3Recruiting
- Sponsor
- Lorestan University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of salbutamol in transient tachypnea of the newborn (TTN) (2 arms), sponsored by Lorestan University of Medical Sciences. Primary endpoints: Duration of tachypnea, Duration of oxygen therapy and 10 more. Started Oct 2026; status: recruiting.
02
Drugs
salbutamol
03
Conditions
transient tachypnea of the newborn (TTN)
Beyond the preview
Go deeper on IRCT20250722066594N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250722066594N1.